Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience

Open Forum Infectious Diseases

Volumn 2, Issue 3, 2015, Pages

  Stempel, Jessica M ^a,b   Hammond, Sarah P ^a,b,c   Sutton, Deanna A ^d   Weiser, Linda M ^a   Marty, Francisco M ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

fungal disease; fusarium; invasive fusariosis; terbinafine; voriconazole

Indexed keywords

EID: 84964899184     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/OFID/OFV099     Document Type: Article

References (33)

1. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Infect Dis 1994; 7:479–504.
2. Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98:315–9.
3. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect 2010; 60:331–7.
4. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237–42.
5. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695–704.
6. Dien Bard J, Mangahis A, Hofstra TC, Bender JM. First case report of bloodstream infection by Rhizomucor pusillus in a child with hemophagocytic lymphohistiocytosis. Med Mycol Case Rep 2014; 5:20–3.
7. Nucci M, Marr KA, Vehreschild MJ, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect 2014; 20:580–5.
8. Azor M, Gené J, Cano J, et al. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moliniforme) and Fusarium thapsinum. Antimicrob Agents Chemother 2008; 52:2228–31.
9. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, et al. Antifungal susceptibility profile of clinical Fusarium spp.: isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805–9.
10. Revankar SG, Nailor MD, Sobel JD. Use of terbinafine in rare and refractory mycoses. Future Microbiol 2008; 3:9–17.
11. Neuburger S, Massenkeil G, Seibold M, et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis 2008; 10:290–3.
12. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–21.
13. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674–83.
14. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101–11.
15. Garnica M, Oliveira de Cunha M, Portugal R, et al. Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients. Clin Infect Dis 2014; 60:875–80.
16. Tortorano AM, Prigitano A, Dho G, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from Northern Italy. Antimicrob Agents Chemother 2008; 52:2683–5.
17. Chang DC, Grant GB, O’Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006; 296:953–63.
18. Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, et al. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother 2015; 70:1068–71.
19. Hsuan HM, Salleh B, Zakaria L. Molecular identification of Fusarium species in Gibberella fujikuroi species complex from rice, sugarcane and maize from Peninsular Malaysia. Int J Mol Sci 2011; 12:6722–32.
20. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122–31.
21. Raad II, Hachem Y, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398–403.
22. Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90:69–80.
23. Azor M, Gené J, Cano J, Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother 2007; 51:1500–3.
24. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46:3298–300.
25. Koehler P, Tacke D, Cornely OA. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi. Crit Rev Microbiol 2014; 9:1–14.
26. Blyth CC, Gilroy NM, Guy SD, et al. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haematopoietic stem cell transplantation, 2014. Intern Med J 2014; 44: 1333–49.
27. Bennett JE. Antifungal agents. Chapt 57. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman and Gillman’s The Pharmacological Basis of Therapeutics, 12th Edition. New York, NY: McGraw-Hill, 2011.
28. Inano S, Kimura M, Iida J, Arima N. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review. J Infect Chemother 2013; 19:1173–80.
29. Spader TB, Venturini TP, Rossato L, et al. Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium. Rev Iberoam Micol 2013; 30:200–4.
30. Ortoneda M, Capilla J, Pastor FJ, et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004; 48:69–71.
31. Stanzani M, Vianelli N, Bandini G, et al. Successful treatment of disseminated fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect 2006; 53:e243–6.
32. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10(Suppl 1):67–75.
33. Horn DL, Freifeld AG, Schuster MG, et al. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance® registry. Mycoses 2014; 57:652–8.